Nov 30 2010
biOasis Technologies Inc. (TSX-V:BTI) announced today that it has commenced a sponsored research agreement with the National Research Council ("NRC") of Canada. Under the terms of the agreement, the NRC will evaluate the ability of biOasis' compounds to cross the blood-brain barrier using time-domain in vivo optical imaging.
"This is an important step in the development of Transcend™," says CEO Rob Hutchison. "The agreement with the NRC will provide the company with demonstration of the ability of TranscendTM to carry a fluorescent dye that is normally excluded from the brain, across the blood-brain barrier. This will enable its visualization and localization in brain tissue and further add to our understanding of the potential for TranscendTM to deliver therapeutic agents into the brain. We anticipate that this information will be of great interest to prospective partners and licensees of biOasis' technologies."
Source: biOasis Technologies Inc.